Why this trial matters: Provides real-world evidence on first-line regimens in a poor-prognosis mCRC subtype Highlights superior survival with chemo + anti-VEGF versus chemo alone or targeted therapy Reinforces the importance of personalized treatment strategies and further trials Eli Lilly Retatrutide Delivers Unprecedented Weight Loss in Phase III TRIUMPH-4 Trial Eli Lillys investigational triple-agonist retatrutide produced an average ~28.7% body-weight reduction (71.2 lbs) at 68 weeks in the Phase III TRIUMPH-4 obesity trial, along with meaningful knee osteoarthritis pain relief, marking one of the strongest weight-loss results reported in late-stage obesity research
Influencers, combat athletes, and aggressive longevity optimization clinics routinely market this peptide combination to millions of consumers, effectively bypassing traditional, conservative medical frameworks and initiating a massive, uncontrolled human trial
The therapeutic implications were obvious: if you could block myostatin in a person on purpose, you might be able to rebuild muscle lost to dystrophy, aging, or as it turns out weight-loss drugs
Potential Drawbacks and Side Effects to Consider Creatine is widely studied and generally well tolerated, but there are still a few considerations to keep in mind
The continuous production of ROS by mitochondria can lead to mitochondrial dysfunction, impaired ATP production, and reduced sperm motility